治疗HER2阳性癌症的有效联合疗法。
Effective Combination Therapies for the Treatment of HER2 Cancer.
作者信息
Kargbo Robert B
机构信息
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
出版信息
ACS Med Chem Lett. 2023 Feb 7;14(3):231-232. doi: 10.1021/acsmedchemlett.2c00544. eCollection 2023 Mar 9.
Abstract
Breast cancer (BC) is the primary cause of cancer-related death among women worldwide. The human epidermal growth factor receptor type 2 (HER2)-positive BC accounts for ∼15% of all BCs and a relatively poor prognosis. The disclosure in this patent highlight relates to a combination therapy comprising inavolisib (GDC-0077) and a HER2-targeted therapy such as trastuzumab, pertuzumab, or their combination for the treatment of HER2-overexpressing breast cancer.
摘要
乳腺癌（BC）是全球女性癌症相关死亡的主要原因。人类表皮生长因子受体2（HER2）阳性乳腺癌约占所有乳腺癌的15%，且预后相对较差。本专利披露的重点涉及一种联合疗法，该疗法包含inavolisib（GDC-0077）和一种HER2靶向疗法，如曲妥珠单抗、帕妥珠单抗或它们的组合，用于治疗HER2过表达的乳腺癌。
相似文献
1
Effective Combination Therapies for the Treatment of HER2 Cancer.治疗HER2阳性癌症的有效联合疗法。
ACS Med Chem Lett. 2023 Feb 7;14(3):231-232. doi: 10.1021/acsmedchemlett.2c00544. eCollection 2023 Mar 9.
2
Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.帕妥珠单抗和 ado-trastuzumab emtansine 对美国局部晚期、炎性或早期 HER2 阳性乳腺癌女性患者复发累积避免的影响。
Adv Ther. 2023 Sep;40(9):3857-3874. doi: 10.1007/s12325-023-02554-6. Epub 2023 Jun 26.
3
Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.曲妥珠单抗在治疗 HER2 阳性转移性乳腺癌中的应用。
Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24.
4
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.使用GDC-0941 PI3K抑制剂、曲妥珠单抗和帕妥珠单抗联合抑制HER2/HER3介导的乳腺癌细胞生长。
Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.
5
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.赫敏：一项随机2期试验，比较MM - 302联合曲妥珠单抗与医生选择的化疗方案联合曲妥珠单抗，用于治疗既往接受过治疗、未使用过蒽环类药物、HER2阳性、局部晚期/转移性乳腺癌患者。
BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z.
6
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.递减策略：HER2 阳性、雌激素受体阴性、淋巴结阴性的早期乳腺癌化疗降阶梯治疗。
Future Oncol. 2023 Aug;19(24):1655-1667. doi: 10.2217/fon-2022-1282. Epub 2023 Aug 23.
7
Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.帕妥珠单抗治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735.
8
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.采用多药HER靶向疗法治疗人表皮生长因子受体2过表达的乳腺癌异种移植瘤。
J Natl Cancer Inst. 2007 May 2;99(9):694-705. doi: 10.1093/jnci/djk151.
9
Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.新辅助帕妥珠单抗联合曲妥珠单抗与化疗方案在中国HER2阳性早期乳腺癌患者中的疗效和安全性：一项真实世界回顾性多中心队列研究
Ann Transl Med. 2022 Dec;10(24):1387. doi: 10.21037/atm-22-6054.
10
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.曲妥珠单抗和帕妥珠单抗固定剂量组合用于皮下注射联合化疗治疗 HER2 阳性早期乳腺癌（FeDeriCa）：一项随机、开放标签、多中心、非劣效性、III 期研究。
Lancet Oncol. 2021 Jan;22(1):85-97. doi: 10.1016/S1470-2045(20)30536-2. Epub 2020 Dec 21.
引用本文的文献
1
Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.变革者：2024年获美国食品药品监督管理局批准的重磅小分子药物
Pharmaceuticals (Basel). 2025 May 15;18(5):729. doi: 10.3390/ph18050729.
2
Two Different Responsive Organosilica Nanocarriers to Combine Chemo- and Immunotherapy against Cancer.两种不同的响应性有机硅纳米载体联合化疗和免疫疗法治疗癌症。
ACS Omega. 2024 Sep 25;9(40):41225-41235. doi: 10.1021/acsomega.4c02838. eCollection 2024 Oct 8.
本文引用的文献
1
Therapeutic landscape of advanced HER2-positive breast cancer in 2022.2022 年晚期 HER2 阳性乳腺癌的治疗性景观。
Med Oncol. 2022 Oct 12;39(12):258. doi: 10.1007/s12032-022-01849-y.
2
Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review.HER2阳性乳腺癌新辅助治疗的进展：一项叙述性综述
Gland Surg. 2022 Aug;11(8):1415-1423. doi: 10.21037/gs-22-439.
3
HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies.非小细胞肺癌中的HER2：新兴疗法综述
Cancers (Basel). 2022 Aug 27;14(17):4155. doi: 10.3390/cancers14174155.
4
Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review.吡咯替尼与节拍性长春瑞滨治疗HER2阳性乳腺癌伴软脑膜转移的持久疗效：一例报告及文献综述
Front Oncol. 2022 Feb 16;12:811919. doi: 10.3389/fonc.2022.811919. eCollection 2022.
5
Gene Expression Profiling in Early Breast Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment Features.基于分子和肿瘤微环境特征的早期乳腺癌患者分层中的基因表达谱分析
Biomedicines. 2022 Jan 24;10(2):248. doi: 10.3390/biomedicines10020248.
6
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities.晚期激素受体阳性、人表皮生长因子受体2阴性乳腺癌对细胞周期蛋白依赖性激酶4/6抑制剂耐药的机制及新出现的治疗机会
Clin Cancer Res. 2022 Mar 1;28(5):821-830. doi: 10.1158/1078-0432.CCR-21-2947.
Zotero 插件